ArticlePrecision radiation oncology2026
C-X-C Motif Chemokine Receptor 4 (CXCR4)-Targeted Biologically Guided Proton Spatially Fractionated Radiotherapy for Bulky Limited-Stage Small Cell Lung Cancer.
Article in Precision radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: To evaluate the feasibility and dosimetric safety of integrating C-X-C motif chemokine receptor 4 (CXCR4)-targeted tracer Materials and Methods: Among 30 patients with bulky limited-stage small-cell lung cancer, a threshold range of 35%-40% of the maximum standard uptake value (SUV Results: CXCR4-defined sub-volumes with low thresholds in BG-pSFRT demonstrated spatial concordance with putative hypoxic sub-volumes in SBRT-PATHY, whereas higher SUV Conclusions: CXCR4-targeted BG-pSFRT may be a dosimetrically feasible strategy for bulky limited-stage small cell lung cancer and demonstrates distinct dosimetric characteristics. The current research findings are limited to the dosimetric level and further clinical trials are required for verification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.